Pfizer and BioNTech Request Regulatory Agencies Expand Emergency Use of Their COVID-19 Vaccine to Adolescents

Is it in the best interests of our children to take the experimental gene therapy when the COVID-19 survival rate is better than 99.9% for this age group and the growing numbers of people experiencing adverse effects from the injection? Not to mention the uncertain/unknown longer-run effects….

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

%d bloggers like this: